Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000391124

Medchemexpress LLC Riviciclib hydrochloride | 920113-03-7 | 99.1% | 438.30 | 100 MG
SDP

Catalog No. 5000391124
Encompass_Preferred

Riviciclib hydrochloride is a potent cyclin-dependent kinase (CDK) inhibitor. It inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively, and shows antitumor activity on cisplatin-resistant cells.

  • Potent cyclin-dependent kinase (CDK) inhibitor.
  • Inhibits CDK9-cyclinT1 (IC50: 20 nM), CDK4-cyclin D1 (IC50: 63 nM), and CDK1-cyclinB (IC50: 79 nM).
  • Shows antitumor activity on cisplatin-resistant cells.
  • Induces G1-G2 arrest and apoptosis in promyelocytic leukemia cells.
  • Reduces cyclin D1, Cdk4, and Rb levels in H-460 cells.
  • Active in various human cancer cell lines including colon carcinoma, osteosarcoma, cervical carcinoma, and bladder carcinoma cells.
  • Significant in vivo efficacy in tumor models, inhibiting growth in human colon carcinoma HCT-116 xenograft and H-460 tumor xenograft in mice.

Catalog No. 50-003-91124 Supplier Medchemexpress LLC Supplier No. HY16559100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Riviciclib hydrochloride is a potent cyclin-dependent kinase (CDK) inhibitor. It inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively, and shows antitumor activity on cisplatin-resistant cells.

  • Potent cyclin-dependent kinase (CDK) inhibitor.
  • Inhibits CDK9-cyclinT1 (IC50: 20 nM), CDK4-cyclin D1 (IC50: 63 nM), and CDK1-cyclinB (IC50: 79 nM).
  • Shows antitumor activity on cisplatin-resistant cells.
  • Induces G1-G2 arrest and apoptosis in promyelocytic leukemia cells.
  • Reduces cyclin D1, Cdk4, and Rb levels in H-460 cells.
  • Active in various human cancer cell lines including colon carcinoma, osteosarcoma, cervical carcinoma, and bladder carcinoma cells.
  • Significant in vivo efficacy in tumor models, inhibiting growth in human colon carcinoma HCT-116 xenograft and H-460 tumor xenograft in mice.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.